Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $40.15 Average Price Target from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned a consensus rating of “Moderate Buy” from the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $40.1538.

Several analysts have commented on the company. Evercore set a $22.00 price objective on Janux Therapeutics in a report on Monday, May 11th. Wedbush reduced their target price on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Truist Financial reiterated a “buy” rating and set a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. UBS Group lowered shares of Janux Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $57.00 to $15.00 in a report on Wednesday, April 15th. Finally, Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th.

Insider Activity

In related news, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total value of $56,947.77. Following the transaction, the insider directly owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. This trade represents a 5.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $14.17, for a total value of $28,878.46. Following the sale, the vice president owned 32,270 shares of the company’s stock, valued at approximately $457,265.90. This trade represents a 5.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.90% of the stock is owned by corporate insiders.

Institutional Trading of Janux Therapeutics

Large investors have recently made changes to their positions in the company. Rhenman & Partners Asset Management AB grew its holdings in shares of Janux Therapeutics by 125.1% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 225,377 shares of the company’s stock worth $3,110,000 after buying an additional 125,250 shares in the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in Janux Therapeutics during the fourth quarter worth about $536,000. SG Americas Securities LLC grew its stake in Janux Therapeutics by 175.1% during the 4th quarter. SG Americas Securities LLC now owns 79,817 shares of the company’s stock valued at $1,101,000 after acquiring an additional 50,802 shares in the last quarter. Profund Advisors LLC grew its stake in Janux Therapeutics by 289.5% during the 4th quarter. Profund Advisors LLC now owns 64,022 shares of the company’s stock valued at $884,000 after acquiring an additional 47,584 shares in the last quarter. Finally, UBS Group AG raised its holdings in Janux Therapeutics by 51.2% in the 4th quarter. UBS Group AG now owns 590,060 shares of the company’s stock valued at $8,143,000 after acquiring an additional 199,703 shares during the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

JANX opened at $16.15 on Wednesday. The company has a fifty day moving average of $14.38 and a two-hundred day moving average of $14.14. The stock has a market capitalization of $984.83 million, a price-to-earnings ratio of -8.78 and a beta of 2.52. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.13. The firm had revenue of $3.73 million for the quarter, compared to analysts’ expectations of $4.36 million. On average, equities research analysts forecast that Janux Therapeutics will post -1.7 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.